解剖与存活心肌引导的完全血运重建对缺血性心肌病患者临床结局的影响
本研究基于REVIVED-BCIS2试验,纳入670例严重左心室功能不全患者,用冠脉血运重建指数(RIcoro)和心肌血运重建指数(RImyo)评估解剖与存活心肌引导的完全血运重建。与单纯优化药物治疗相比,完全解剖或存活心肌引导的血运重建均未改善无事件生存(HR 0.90,95%CI 0.62-1.32;HR 0.95,95%CI 0.66-1.35)。
要点
- 严重左室功能不全患者中,完全解剖血运重建未改善死亡或心衰住院风险。
- 存活心肌引导的完全血运重建同样未带来无事件生存获益。
- 残余SYNTAX评分敏感性分析未显示与结局相关。
核心结论
- 在严重左室功能不全患者中,无论解剖还是存活心肌引导的完全血运重建,均未较不完全血运重建或单纯药物治疗改善无事件生存。
研究设计与样本
- REVIVED-BCIS2试验的回顾性分析,纳入700例随机患者中670例有基线/术中造影和存活研究可分析者。
- 用RIcoro和RImyo分别评估解剖和存活心肌引导的血运重建完全性,按中位数分为完全与不完全。
主要发现
- 基线BCIS-JS中位数8(Q1-Q3: 6-10),SYNTAX评分中位数22(Q1-Q3: 15-29)。
- PCI组RIcoro和RImyo中位数分别为67%和85%。
- 完全解剖血运重建与单纯优化药物治疗相比,主要结局HR 0.90(95%CI 0.62-1.32)。
- 完全存活心肌引导血运重建与单纯优化药物治疗相比,主要结局HR 0.95(95%CI 0.66-1.35)。
- 残余SYNTAX评分敏感性分析未显示与结局相关。
关键数值与推荐
- RIcoro = BCIS-JS变化值 / 基线BCIS-JS。
- RImyo = 血运重建存活节段数 / 病变血管供应的存活节段数。
- 主要结局为死亡或心衰住院。
临床怎么用
- 对于严重左室功能不全的缺血性心肌病患者,追求解剖或存活心肌引导的完全血运重建未显示额外临床获益。
- 血运重建决策需综合评估,不宜仅以解剖或存活心肌完全性作为改善预后的目标。
局限性
- 分析仅纳入有基线/术中造影和存活研究可分析的患者(670/700)。
- 完全与不完全血运重建按RI中位数二分,可能受样本量限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Complete revascularization of coronary artery disease has been linked to improved outcomes in patients with preserved left ventricular (LV) function. OBJECTIVES: This study sought to identify the impact of complete revascularization in patients with severe LV dysfunction. METHODS: Patients enrolled in the REVIVED-BCIS2 (Revascularization for Ischemic Ventricular Dysfunction) trial were eligible if baseline/procedural angiograms and viability studies were available for analysis by independent core laboratories. Anatomical and viability-guided completeness of revascularization were measured by the coronary and myocardial revascularization indices (RIcoro and RImyo), respectively, where RIcoro = (change in British Cardiovascular Intervention Society Jeopardy score [BCIS-JS]) / (baseline BCIS-JS) and RImyo= (number of revascularized viable segments) / (number of viable segments supplied by diseased vessels). The percutaneous coronary intervention (PCI) group was classified as having complete or incomplete revascularization by median RIcoro and RImyo. The primary outcome was death or hospitalization for heart failure. RESULTS: Of 700 randomized patients, 670 were included. The baseline BCIS-JS and SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores were 8 (Q1-Q3: 6-10) and 22 (Q1-Q3: 15-29), respectively. In those patients assigned to PCI, median RIcoro and RImyo values were 67% and 85%, respectively. Compared with the group assigned to optimal medical therapy alone, there was no difference in the likelihood of the primary outcome in those patients receiving complete anatomical or viability-guided revascularization (HR: 0.90; 95% CI: 0.62-1.32; and HR: 0.95; 95% CI: 0.66-1.35, respectively). A sensitivity analysis by residual SYNTAX score showed no association with outcome. CONCLUSIONS: In patients with severe LV dysfunction, neither complete anatomical nor viability-guided revascularization was associated with improved event-free survival compared with incomplete revascularization or treatment with medical therapy alone. (Revascularization for Ischemic Ventricular Dysfunction) [REVIVED-BCIS2]; NCT01920048).
引用
- Ezad SM, McEntegart M, Dodd M, et al. Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. J Am Coll Cardiol. 2024. PMID: 38759904. doi:10.1016/j.jacc.2024.04.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。